Home LiteratureArticle Details
PMID: 7565411 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S. Review

Immune regulation in Epstein-Barr virus-associated diseases.

Microbiological reviews ·Vol. 59 ·No. 3 ·1995-09-00 ·Pages 387-405

Khanna R, Burrows SR, Moss DJ

Abstract

Epstein-Barr virus (EBV) is a member of the human herpesvirus family and, like many other herpesviruses, maintains a lifelong latent association with B lymphocytes and a permissive association with stratified epithelium in the oropharynx. Clinical manifestations of primary EBV infection range from acute infectious mononucleosis to an asymptomatic persistent infection. EBV is also associated with a number of malignancies in humans. This review discusses features of the biology of the virus, both in cell culture systems and in the natural host, before turning to the role of the immune system in controlling EBV infection in healthy individuals and in individuals with EBV-associated diseases. Cytotoxic T cells that recognize virally determined epitopes on infected cells make up the major effector arm and control the persistent infection. In contrast, the options for immune control of EBV-associated malignancies are more restricted. Not only is antigen expression restricted to a single nuclear antigen, EBNA1, but also these tumor cells are unable to process EBV latent antigens, presumably because of a transcriptional defect in antigen-processing genes (such as TAP1 and TAP2). The likelihood of producing a vaccine capable of controlling the acute viral infection and EBV-associated malignancies is also discussed.

MeSH Terms
Antibody Formation Burkitt Lymphoma/immunology Herpesviridae Infections/complications,immunology,virology Herpesvirus 4, Human/classification,genetics,pathogenicity Hodgkin Disease/immunology Humans Immunity, Cellular Nasopharyngeal Neoplasms/immunology T-Lymphocytes, Cytotoxic/immunology Tumor Virus Infections/complications,immunology,virology Viral Vaccines
Chemicals
Viral Vaccines
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Khanna R
Queensland Institute of Medical Research, Bancroft Centre, Herston, Australia.
Burrows S R
Moss D J
References (249)
249 references, click to expand
  1. Restricted expression of EBV latent genes and T-lymphocyte-detected membrane antigen in Burkitt's lymphoma cells.
    EMBO J. 1986 Oct;5(10):2599-607 PMID: 3023050
  2. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein.
    J Virol. 1990 May;64(5):2126-34 PMID: 2157875
  3. Prevention of Epstein-Barr (EB) virus-induced lymphoma in cottontop tamarins by vaccination with the EB virus envelope glycoprotein gp340 incorporated into immune-stimulating complexes.
    J Gen Virol. 1988 Aug;69 ( Pt 8):2093-6 PMID: 2841417
  4. A re-examination of the Epstein-Barr virus carrier state in healthy seropositive individuals.
    Int J Cancer. 1985 Jan 15;35(1):35-42 PMID: 2981780
  5. Nucleotide sequences of the joint between the L and S segments of herpes simplex virus types 1 and 2.
    J Gen Virol. 1981 Aug;55(Pt 2):315-31 PMID: 6270266
  6. Hodgkin's cells express a novel pattern of adhesion molecules.
    Clin Exp Immunol. 1992 Oct;90(1):117-23 PMID: 1395091
  7. Molecular genetic analysis of lymphoid tumors arising after organ transplantation.
    Am J Pathol. 1989 Dec;135(6):977-87 PMID: 2556930
  8. Infectious mononucleosis and Hodgkin's disease.
    Int J Cancer. 1978 Jul 15;22(1):10-3 PMID: 681023
  9. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. I. Complete regression of virus-induced transformation in cultures of seropositive donor leukocytes.
    Int J Cancer. 1978 Dec;22(6):662-8 PMID: 214405
  10. Cell-mediated immunity to Epstein-Barr-virus-transformed lymphoblastoid cells in acute infectious mononucleosis.
    N Engl J Med. 1975 Dec 4;293(23):1159-63 PMID: 171568
  11. Thymic origin of atypical lymphoid cells in infectious mononucleosis.
    Lancet. 1973 May 26;1(7813):1153-5 PMID: 4123541
  12. Proteasome subunits encoded by the major histocompatibility complex are not essential for antigen presentation.
    Nature. 1992 Nov 12;360(6400):174-7 PMID: 1299222
  13. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI.
    Science. 1990 Jun 8;248(4960):1230-4 PMID: 2161559
  14. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism.
    Science. 1992 Mar 20;255(5051):1578-80 PMID: 1312750
  15. Characterization of the T cell-mediated cellular cytotoxicity during acute infectious mononucleosis.
    J Immunol. 1989 Jul 15;143(2):660-70 PMID: 2472449
  16. Various forms of Epstein-Barr virus infection in man: established facts and a general concept.
    Lancet. 1973 Oct 13;2(7833):836-9 PMID: 4126630
  17. Infection of human thymocytes by Epstein-Barr virus.
    J Exp Med. 1991 Apr 1;173(4):971-80 PMID: 1706754
  18. Infectious mononucleosis: model for self-limiting lymphoproliferation.
    Lancet. 1975 Apr 12;1(7911):846-9 PMID: 48066
  19. Epstein-Barr virus latent membrane protein expression in Hodgkin and Reed-Sternberg cells.
    Proc Natl Acad Sci U S A. 1991 Jun 1;88(11):4766-70 PMID: 1647016
  20. Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease.
    Leukemia. 1993 Apr;7(4):580-5 PMID: 8464236
  21. Delayed cutaneous hypersensitivity reactions to autologous extracts of Burkitt-lymphoma cells.
    N Engl J Med. 1970 Apr 2;282(14):776-80 PMID: 5416971
  22. Epstein-Barr virus (EBV)-encoded membrane protein LMP1 from a nasopharyngeal carcinoma is non-immunogenic in a murine model system, in contrast to a B cell-derived homologue.
    Eur J Cancer. 1994;30A(1):84-8 PMID: 8142171
  23. Alternative involvement of two cytogenetically distinguishable breakpoints on chromosome 8 in Burkitt's lymphoma associated translocations.
    Cancer Genet Cytogenet. 1986 Feb 1;20(1-2):95-9 PMID: 3943061
  24. Replication of Epstein-Barr virus within the epithelial cells of oral "hairy" leukoplakia, an AIDS-associated lesion.
    N Engl J Med. 1985 Dec 19;313(25):1564-71 PMID: 2999595
  25. Defective regulation of Epstein-Barr virus infection in patients with acquired immunodeficiency syndrome (AIDS) or AIDS-related disorders.
    N Engl J Med. 1986 Apr 3;314(14):874-9 PMID: 3005862
  26. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas.
    J Med Virol. 1988 Jun;25(2):189-95 PMID: 2839612
  27. Paired Epstein-Barr virus-carrying lymphoma and lymphoblastoid cell lines from Burkitt's lymphoma patients: comparative sensitivity to non-specific and to allo-specific cytotoxic responses in vitro.
    Int J Cancer. 1984 Sep 15;34(3):339-48 PMID: 6090321
  28. Delineation of the cis-acting element mediating EBNA-2 transactivation of latent infection membrane protein expression.
    J Virol. 1991 Dec;65(12):6765-71 PMID: 1658373
  29. Epstein-Barr virus latent membrane protein (LMP1) and nuclear proteins 2 and 3C are effectors of phenotypic changes in B lymphocytes: EBNA-2 and LMP1 cooperatively induce CD23.
    J Virol. 1990 May;64(5):2309-18 PMID: 2157887
  30. Increased sensitivity of human lymphoid lines to natural killer cells after induction of the Epstein-Barr viral cycle by superinfection or sodium butyrate.
    J Exp Med. 1980 Mar 1;151(3):614-27 PMID: 6244358
  31. MORPHOLOGICAL AND BIOLOGICAL STUDIES ON A VIRUS IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.
    J Exp Med. 1965 May 1;121:761-70 PMID: 14278230
  32. Demonstration of monoclonal EBV genomes in Hodgkin's disease and Ki-1-positive anaplastic large cell lymphoma by combined Southern blot and in situ hybridization.
    Blood. 1989 Aug 1;74(2):810-6 PMID: 2546633
  33. Synchronous and sequential activation of latently infected Epstein-Barr virus genomes.
    J Virol. 1989 Jan;63(1):445-9 PMID: 2462063
  34. Immunofluorescence in cells derived from Burkitt's lymphoma.
    J Bacteriol. 1966 Mar;91(3):1248-56 PMID: 4160230
  35. Cytotoxic T cell recognition of Epstein-Barr virus-infected B cells. I. Specificity and HLA restriction of effector cells reactivated in vitro.
    Eur J Immunol. 1981 Sep;11(9):686-93 PMID: 6170517
  36. Marker band in one chromosome 14 from Burkitt lymphomas.
    Nature. 1972 May 5;237(5349):33-4 PMID: 4113130
  37. Cross-reactivity of self-HLA-restricted Epstein-Barr virus-specific cytotoxic T lymphocytes for allo-HLA determinants.
    J Exp Med. 1983 Dec 1;158(6):1804-21 PMID: 6196431
  38. Cell-mediated immunosurveillance mechanisms and the pathogenesis of Burkitt's lymphoma.
    IARC Sci Publ. 1985;(60):249-64 PMID: 2998992
  39. Induction of the Epstein-Barr virus (EBV) cycle in latently infected cells by n-butyrate.
    Virology. 1979 Apr 15;94(1):228-31 PMID: 220786
  40. Latent and replicating forms of Epstein-Barr virus DNA in lymphomas and lymphoproliferative diseases.
    J Infect Dis. 1989 Oct;160(4):589-98 PMID: 2551973
  41. Influence of the Epstein-Barr virus nuclear antigen EBNA 2 on the growth phenotype of virus-transformed B cells.
    J Virol. 1987 May;61(5):1310-7 PMID: 3033261
  42. Reactivation of Epstein-Barr virus in Sjögren's syndrome.
    Springer Semin Immunopathol. 1991;13(2):217-31 PMID: 1664987
  43. Suppression of in vitro Epstein-Barr virus infection. A new role for adult human T lymphocytes.
    J Exp Med. 1977 Aug 1;146(2):495-508 PMID: 195004
  44. Virologic, immunologic, and clinical observations on a patient during the incubation, acute, and convalescent phases of infectious mononucleosis.
    Clin Immunol Immunopathol. 1984 Mar;30(3):437-50 PMID: 6199144
  45. Linkage of a nasopharyngeal carcinoma susceptibility locus to the HLA region.
    Nature. 1990 Aug 2;346(6283):470-1 PMID: 2377207
  46. Expression of CR2/EBV receptors on human thymocytes detected by monoclonal antibodies.
    Eur J Immunol. 1988 Aug;18(8):1299-302 PMID: 2970972
  47. Multiple HLA A11-restricted cytotoxic T-lymphocyte epitopes of different immunogenicities in the Epstein-Barr virus-encoded nuclear antigen 4.
    J Virol. 1993 Mar;67(3):1572-8 PMID: 7679748
  48. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity.
    Proc Natl Acad Sci U S A. 1980 Sep;77(9):5307-11 PMID: 6254073
  49. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development.
    J Exp Med. 1992 Jul 1;176(1):169-76 PMID: 1377222
  50. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. III. Activation of cytotoxic T cells in virus-infected leukocyte cultures.
    Int J Cancer. 1979 May 15;23(5):618-25 PMID: 222691
  51. Epstein-Barr virus (EBV) and X-linked lymphoproliferative syndrome (XLP).
    AIDS Res. 1986 Dec;2 Suppl 1:S109-13 PMID: 3030340
  52. Possible involvement of Epstein-Barr virus in polyclonal B cell activation in Sjögren's syndrome.
    Arthritis Rheum. 1988 Aug;31(8):1014-21 PMID: 2841943
  53. Homology between Epstein-Barr virus DNA and viral DNA from Burkitt's lymphoma and nasopharyngeal carcinoma determined by DNA-DNA reassociation kinetics.
    Nature. 1973 Mar 2;242(5392):44-7 PMID: 4348458
  54. EBV peptide epitope sensitization restores human cytotoxic T cell recognition of Burkitt's lymphoma cells. Evidence for a critical role for ICAM-2.
    J Immunol. 1993 Jun 1;150(11):5154-62 PMID: 7684421
  55. Burkitt's lymphoma outside the known endemic areas of Africa and New Guinea.
    Int J Cancer. 1967 Nov 15;2(6):562-5 PMID: 5582262
  56. Cytotoxic T lymphocytes show HLA-C-restricted recognition of EBV-bearing cells and allorecognition of HLA class I molecules presenting self-peptides.
    J Immunol. 1992 Oct 1;149(7):2406-14 PMID: 1326579
  57. Differential reactivity of human serums with early antigens induced by Epstein-Barr virus.
    Science. 1970 Jul 10;169(3941):188-90 PMID: 4316788
  58. Epstein-Barr virus types 1 and 2 differ in their EBNA-3A, EBNA-3B, and EBNA-3C genes.
    J Virol. 1990 Sep;64(9):4084-92 PMID: 2166806
  59. Down-regulation of class I HLA antigens and of the Epstein-Barr virus-encoded latent membrane protein in Burkitt lymphoma lines.
    Proc Natl Acad Sci U S A. 1987 Jul;84(13):4567-71 PMID: 3037521
  60. Immune surveillance against Epstein-Barr virus.
    Semin Immunol. 1992 Apr;4(2):97-104 PMID: 1377517
  61. Studies of EBV-lymphoid cell interactions in two patients with the X-linked lymphoproliferative syndrome: normal EBV-specific HLA-restricted cytotoxicity.
    Clin Exp Immunol. 1986 Feb;63(2):280-9 PMID: 3009061
  62. Conservation and progressive methylation of Epstein-Barr viral DNA sequences in transformed cells.
    J Virol. 1981 Apr;38(1):305-16 PMID: 6264105
  63. The transforming domain alone of the latent membrane protein of Epstein-Barr virus is toxic to cells when expressed at high levels.
    J Virol. 1989 Jun;63(6):2469-75 PMID: 2542565
  64. Epstein-Barr virus gene expression in nasopharyngeal carcinoma.
    J Gen Virol. 1988 May;69 ( Pt 5):1051-65 PMID: 2836550
  65. Characterization of two Epstein-Barr virus epitopes restricted by HLA-B7.
    Eur J Immunol. 1995 Jan;25(1):18-24 PMID: 7531143
  66. CpG methylation of viral DNA in EBV-associated tumours.
    Int J Cancer. 1990 Jun 15;45(6):1125-30 PMID: 2161800
  67. Host cell macromolecular synthesis in cells containing EBV-induced early antigens, studied by combined immunofluorescence and radioautography.
    Virology. 1971 Jul;45(1):22-9 PMID: 4329587
  68. Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes.
    J Virol. 1992 Jan;66(1):122-31 PMID: 1309242
  69. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23.
    J Virol. 1990 Mar;64(3):1002-13 PMID: 2154588
  70. Immunoglobulin class and subclass deficiencies prior to Epstein-Barr virus infection in males with X-linked lymphoproliferative disease.
    Am J Med Genet. 1991 Sep 1;40(3):294-7 PMID: 1683154
  71. Comparison of Epstein-Barr virus strains of different origin by analysis of the viral DNAs.
    J Virol. 1980 Sep;35(3):603-18 PMID: 6252328
  72. Formation of intranuclear replication compartments of Epstein-Barr virus with redistribution of BZLF1 and BMRF1 gene products.
    Virology. 1991 Nov;185(1):309-15 PMID: 1656589
  73. Presentation of endogenous viral peptide epitopes by anti-CD40 stimulated human B cells following recombinant vaccinia infection.
    J Immunol Methods. 1993 Aug 26;164(1):41-9 PMID: 7689619
  74. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo.
    J Virol. 1982 Aug;43(2):730-6 PMID: 6287039
  75. Epstein-Barr virus DNA. IX. Variation among viral DNAs from producer and nonproducer infected cells.
    J Virol. 1981 May;38(2):632-48 PMID: 6264134
  76. The suppression of Epstein-Barr virus infection in vitro occurs after infection but before transformation of the cell.
    J Immunol. 1980 Feb;124(2):745-51 PMID: 6243331
  77. Herpes-type virus and chromosome marker in normal leukocytes after growth with irradiated Burkitt cells.
    Science. 1967 Sep 1;157(3792):1064-5 PMID: 6036237
  78. Empty MHC class I molecules come out in the cold.
    Nature. 1990 Aug 2;346(6283):476-80 PMID: 2198471
  79. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells.
    EMBO J. 1987 Sep;6(9):2743-51 PMID: 2824192
  80. Precipitating antibody in human serum to an antigen present in cultured burkitt's lymphoma cells.
    Proc Natl Acad Sci U S A. 1966 Dec;56(6):1699-704 PMID: 16591407
  81. Donor T cells to treat EBV-associated lymphoma.
    N Engl J Med. 1994 Sep 8;331(10):679-80 PMID: 8052285
  82. Epstein-Barr virus-infected B cells persist in the circulation of acyclovir-treated virus carriers.
    Int J Cancer. 1989 Jan 15;43(1):67-71 PMID: 2536009
  83. DNA of Epstein-Barr virus. VI. Mapping of the internal tandem reiteration.
    J Virol. 1979 Aug;31(2):315-24 PMID: 225556
  84. Immunogenetic aspects of nasopharyngeal carcinoma. IV. Increased risk in Chinese of nasopharyngeal carcinoma associated with a Chinese-related HLA profile (A2, Singapore 2).
    J Natl Cancer Inst. 1976 Nov;57(5):977-80 PMID: 1003552
  85. HLA antigen-related restriction of T lymphocyte cytotoxicity to Epstein-Barr virus.
    Proc Natl Acad Sci U S A. 1980 Jul;77(7):4247-50 PMID: 6254017
  86. Cantonese-style salted fish as a cause of nasopharyngeal carcinoma: report of a case-control study in Hong Kong.
    Cancer Res. 1986 Feb;46(2):956-61 PMID: 3940655
  87. Loss of heterozygosity on the short arm of chromosome 3 in nasopharyngeal carcinoma.
    Cancer Genet Cytogenet. 1991 Jul 1;54(1):91-9 PMID: 1676610
  88. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2.
    Proc Natl Acad Sci U S A. 1984 Dec;81(23):7632-6 PMID: 6209719
  89. Presentation of viral antigen by MHC class I molecules is dependent on a putative peptide transporter heterodimer.
    Nature. 1992 Feb 13;355(6361):644-6 PMID: 1538752
  90. Downregulation of cell adhesion molecules LFA-3 and ICAM-1 in Epstein-Barr virus-positive Burkitt's lymphoma underlies tumor cell escape from virus-specific T cell surveillance.
    J Exp Med. 1988 Jun 1;167(6):1811-24 PMID: 2898508
  91. Characterization of the serological response in man to the latent membrane protein and the six nuclear antigens encoded by Epstein-Barr virus.
    J Gen Virol. 1988 Jun;69 ( Pt 6):1217-28 PMID: 2838572
  92. Differential activation of cytotoxic responses by Burkitt's lymphoma (BL)-cell lines: relationship to the BL-cell surface phenotype.
    Cell Immunol. 1986 Oct 1;102(1):99-112 PMID: 3026651
  93. T-cell lymphomas containing Epstein-Barr viral DNA in patients with chronic Epstein-Barr virus infections.
    N Engl J Med. 1988 Mar 24;318(12):733-41 PMID: 2831453
  94. DNA of Epstein-Barr virus. IV. Linkage map of restriction enzyme fragments of the B95-8 and W91 strains of Epstein-Barr Virus.
    J Virol. 1978 Nov;28(2):524-42 PMID: 214576
  95. DNA of herpesvirus pan, a third member of the Epstein-Barr virus-Herpesvirus papio group.
    J Virol. 1982 Mar;41(3):931-9 PMID: 6284982
  96. Epstein-Barr virus markers in a series of Burkitt's lymphomas from the West Nile District, Uganda.
    Eur J Cancer Clin Oncol. 1983 Oct;19(10):1393-404 PMID: 6315443
  97. T-cell-mediated inhibition of EBV-induced B-cell transformation: recognition of virus particles.
    Int J Cancer. 1988 Sep 15;42(3):359-64 PMID: 2843474
  98. Epstein-Barr virus (EBV) antigen-specific leukocyte migration inhibition in infectious mononucleosis. II. Kinetics of sensitization against five EBV-encoded nuclear proteins and the latent membrane protein.
    Clin Immunol Immunopathol. 1989 Jun;51(3):396-405 PMID: 2470542
  99. Multiple HLA class I-dependent cytotoxicities constitute the "non-HLA-restricted" response in infectious mononucleosis.
    Eur J Immunol. 1987 Jul;17(7):1007-13 PMID: 2440688
  100. Role for the Epstein-Barr virus nuclear antigen 2 in viral promoter switching during initial stages of infection.
    Proc Natl Acad Sci U S A. 1991 May 1;88(9):3942-6 PMID: 1850841
  101. Detection of IgG and IgA antibodies to Epstein-Barr virus membrane antigen in sera from patients with nasopharyngeal carcinoma and from normal individuals.
    Int J Cancer. 1986 May 15;37(5):689-91 PMID: 3009331
  102. T cell-T cell killing is induced by specific epitopes: evidence for an apoptotic mechanism.
    J Exp Med. 1991 Mar 1;173(3):681-6 PMID: 1705281
  103. Epstein-Barr virus infection precedes clonal expansion in Burkitt's and acquired immunodeficiency syndrome-associated lymphoma.
    Blood. 1991 Mar 1;77(5):1092-5 PMID: 1847310
  104. Analysis of the defects responsible for the impaired regulation of Epstein-Barr virus-induced B cell proliferation by rheumatoid arthritis lymphocytes. I. Diminished gamma interferon production in response to autologous stimulation.
    J Exp Med. 1983 Jan 1;157(1):173-88 PMID: 6294213
  105. An Epstein-Barr virus-specific cytotoxic T-cell epitope present on A- and B-type transformants.
    J Virol. 1990 Aug;64(8):3974-6 PMID: 1695259
  106. Elevated expression of ICAM1 (CD54) and minimal expression of LFA3 (CD58) in Epstein-Barr-virus-positive nasopharyngeal carcinoma cells.
    Int J Cancer. 1992 Apr 1;50(6):863-7 PMID: 1372880
  107. Apoptotic cell death of primed CD45RO+ T lymphocytes in Epstein-Barr virus-induced infectious mononucleosis.
    Blood. 1992 Jul 15;80(2):452-8 PMID: 1320953
  108. New type B isolates of Epstein-Barr virus from Burkitt's lymphoma and from normal individuals in endemic areas.
    J Gen Virol. 1987 Nov;68 ( Pt 11):2853-62 PMID: 2824665
  109. Immunogenetic aspects of nasopharyngeal carcinoma: I. Differences in HL-A antigen profiles between patients and control groups.
    Int J Cancer. 1974 Jan 15;13(1):122-34 PMID: 4131857
  110. Detection of X-linked lymphoproliferative disease using molecular and immunovirologic markers.
    Am J Med. 1989 Oct;87(4):421-4 PMID: 2572169
  111. Induction of the EBV cycle in B-lymphocyte-derived lines is accompanied by increased natural killer (NK) sensitivity and the expression of EBV-related antigen(s) detected by the ADCC reaction.
    Int J Cancer. 1980 Sep 15;26(3):365-71 PMID: 6270007
  112. Immunological surveillance against neoplasia.
    Harvey Lect. 1973-1974;(69):71-102 PMID: 4376812
  113. Epstein-Barr virus-induced proteins. III. Analysis of polypeptides from P3HR-1-EBV-superinfected NC37 cells by immunoprecipitation.
    Virology. 1980 Apr 15;102(1):231-3 PMID: 6245505
  114. Defective immune surveillance in viral carcinogenesis.
    Lab Invest. 1984 Oct;51(4):373-85 PMID: 6090808
  115. Differential cellular susceptibility to Epstein-Barr virus infection in a patient with X-linked lymphoproliferative disease.
    J Med Virol. 1990 Sep;32(1):47-52 PMID: 2173737
  116. Soluble factor requirements for the autostimulatory growth of B lymphoblasts immortalized by Epstein-Barr virus.
    J Exp Med. 1984 May 1;159(5):1554-9 PMID: 6325575
  117. HLA-A11 epitope loss isolates of Epstein-Barr virus from a highly A11+ population.
    Science. 1993 Apr 2;260(5104):98-100 PMID: 7682013
  118. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element.
    Proc Natl Acad Sci U S A. 1990 Oct;87(19):7390-4 PMID: 2170976
  119. Establishment of cell lines from peripheral leucocytes in infectious mononucleosis.
    Nature. 1967 Nov 25;216(5117):810-1 PMID: 6074953
  120. Final case reporting from the Ugandan prospective study of the relationship between EBV and Burkitt's lymphoma.
    Int J Cancer. 1982 Apr 15;29(4):397-400 PMID: 6282763
  121. Epstein-Barr viral DNA in tissues of Hodgkin's disease.
    Am J Pathol. 1987 Oct;129(1):86-91 PMID: 2821817
  122. Cytogenetic studies on African Burkitt's lymphoma cell lines: t(8;14), t(2;8) and t(8;22) translocations.
    Cancer Genet Cytogenet. 1981 Jun;3(4):307-15 PMID: 7260888
  123. Cytotoxic T-cell clones discriminate between A- and B-type Epstein-Barr virus transformants.
    Nature. 1988 Feb 25;331(6158):719-21 PMID: 2830541
  124. Cross-linking of cell surface immunoglobulins induces Epstein-Barr virus in Burkitt lymphoma lines.
    Int J Cancer. 1984 Jan 15;33(1):27-32 PMID: 6319296
  125. Expression of CD45R0 (UCHL1) by CD4+ and CD8+ T cells as a sign of in vivo activation in infectious mononucleosis.
    Clin Exp Immunol. 1991 Mar;83(3):447-51 PMID: 1672270
  126. In vitro T cell responses to a candidate Epstein-Barr virus vaccine: human CD4+ T cell clones specific for the major envelope glycoprotein gp340.
    Eur J Immunol. 1988 Nov;18(11):1689-97 PMID: 2904885
  127. Demonstration of Epstein-Barr virus in primary brain lymphoma by in situ DNA hybridisation in paraffin wax embedded tissue.
    J Clin Pathol. 1990 Mar;43(3):220-3 PMID: 2159030
  128. Epstein-Barr virus-associated lymphoproliferative disorders in immunocompromised individuals.
    Adv Cancer Res. 1991;57:329-80 PMID: 1659123
  129. T lymphocytes in infectious mononucleosis. II. Response in vitro to interleukin-2 and establishment of T cell lines.
    Clin Exp Immunol. 1985 Apr;60(1):70-7 PMID: 3874018
  130. Coinfection with A- and B-type Epstein-Barr virus in human immunodeficiency virus-positive subjects.
    J Infect Dis. 1990 Sep;162(3):643-8 PMID: 2167337
  131. Epstein-Barr virus gene expression in P3HR1-superinfected Raji cells.
    J Virol. 1987 Oct;61(10):3120-32 PMID: 3041034
  132. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element.
    J Virol. 1991 Aug;65(8):4101-6 PMID: 1649318
  133. Sequence variation of cytotoxic T cell epitopes in different isolates of Epstein-Barr virus.
    Eur J Immunol. 1992 Jan;22(1):183-9 PMID: 1370413
  134. Circulating Epstein-Barr virus-carrying B cells in acute malaria.
    Lancet. 1991 Apr 13;337(8746):876-8 PMID: 1672968
  135. Epstein-Barr virus in nasal T-cell lymphomas in patients with lethal midline granuloma.
    Lancet. 1990 Jan 20;335(8682):128-30 PMID: 1967431
  136. Epstein-Barr virus infection in carcinoma of the salivary gland.
    J Virol. 1991 Dec;65(12):7032-6 PMID: 1658395
  137. Epstein-Barr virus (EBV) antigens processed and presented by B cells, B blasts, and macrophages trigger T-cell-mediated inhibition of EBV-induced B-cell transformation.
    J Virol. 1990 Mar;64(3):1398-401 PMID: 2154620
  138. One of two Epstein-Barr virus nuclear antigens contains a glycine-alanine copolymer domain.
    Proc Natl Acad Sci U S A. 1983 Sep;80(18):5665-9 PMID: 6310587
  139. Sequence analysis of Raji Epstein-Barr virus DNA.
    Virology. 1988 Jun;164(2):334-40 PMID: 2835854
  140. Persisting oncogenic herpesvirus induced by the tumour promotor TPA.
    Nature. 1978 Mar 23;272(5651):373-5 PMID: 204874
  141. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation.
    Lancet. 1995 Jan 7;345(8941):9-13 PMID: 7799740
  142. EBV-determined nuclear antigen (EBNA)-positive cells in the peripheral blood of infectious mononucleosis patients.
    Int J Cancer. 1976 Jan 15;17(1):21-6 PMID: 55396
  143. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes.
    Virology. 1985 Mar;141(2):221-34 PMID: 3002016
  144. Potential antigenic targets on Epstein-Barr virus-associated tumours and the host response.
    Ciba Found Symp. 1994;187:4-13; discussion 13-20 PMID: 7796675
  145. The pathogenesis of Burkitt's lymphoma.
    Adv Cancer Res. 1990;55:133-270 PMID: 2166998
  146. Epstein-Barr virus in acquired immune deficiency syndrome (AIDS) and non-AIDS primary central nervous system lymphoma.
    Cancer. 1992 Sep 15;70(6):1607-11 PMID: 1325277
  147. Characterization of the Epstein-Barr virion-associated DNA polymerase as isolated from superinfected and drug-stimulated cells.
    Biochim Biophys Acta. 1981 Nov 27;656(1):76-85 PMID: 6272863
  148. A comparison of Epstein-Barr virus-specific T-cell immunity in malaria-endemic and -nonendemic regions of Papua New Guinea.
    Int J Cancer. 1983 Jun 15;31(6):727-32 PMID: 6305850
  149. Differentiation-dependent sensitivity of human B-cell-derived lines to major histocompatibility complex-restricted T-cell cytotoxicity.
    Proc Natl Acad Sci U S A. 1986 Aug;83(15):5620-4 PMID: 3016710
  150. A survey of Epstein-Barr virus gene expression in sporadic non-Hodgkin's lymphomas. Detection of Epstein-Barr virus in a subset of peripheral T-cell lymphomas.
    Am J Pathol. 1992 Jun;140(6):1315-25 PMID: 1318639
  151. The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.
    J Virol. 1992 Dec;66(12):7461-8 PMID: 1331531
  152. Identification of an Epstein-Barr virus early gene encoding a second component of the restricted early antigen complex.
    Virology. 1987 Sep;160(1):151-61 PMID: 2820125
  153. High frequency of cross-reactive cytotoxic T lymphocytes elicited during the virus-induced polyclonal cytotoxic T lymphocyte response.
    J Exp Med. 1993 Feb 1;177(2):317-27 PMID: 8093891
  154. HLA A2.1-restricted cytotoxic T cells recognizing a range of Epstein-Barr virus isolates through a defined epitope in latent membrane protein LMP2.
    J Virol. 1993 Dec;67(12):7428-35 PMID: 7693972
  155. Effect of n-butyrate on cellular and viral DNA synthesis in cells latently infected with Epstein-Barr virus.
    Virology. 1980 Dec;107(2):557-61 PMID: 6256952
  156. Long-term T-cell-mediated immunity to Epstein-Barr virus.
    Cancer Res. 1981 Nov;41(11 Pt 1):4216-21 PMID: 6272965
  157. Effect of 12-O-tetradecanoyl-phorbol-13-acetate on the replication of Epstein-Barr virus. I. Characterization of viral DNA.
    Virology. 1979 Nov;99(1):183-7 PMID: 227161
  158. Epstein Barr virus nuclear antigen positive lymphoma after cyclosporin A treatment in patient with renal allograft.
    Lancet. 1980 Jun 21;1(8182):1355-6 PMID: 6104142
  159. Human c-myc onc gene is located on the region of chromosome 8 that is translocated in Burkitt lymphoma cells.
    Proc Natl Acad Sci U S A. 1982 Dec;79(24):7824-7 PMID: 6961453
  160. Primary cerebral lymphoma: a study of 47 cases probed for Epstein-Barr virus genome.
    J Clin Pathol. 1992 Jul;45(7):587-90 PMID: 1325479
  161. Epstein-Barr virus and CD30+ malignant lymphomas.
    Crit Rev Oncog. 1993;4(2):191-239 PMID: 8380546
  162. CULTIVATION IN VITRO OF HUMAN LYMPHOBLASTS FROM BURKITT'S MALIGNANT LYMPHOMA.
    Lancet. 1964 Feb 1;1(7327):252-3 PMID: 14090852
  163. Genetic relations between varicella-zoster virus and Epstein-Barr virus.
    J Gen Virol. 1987 Apr;68 ( Pt 4):1067-79 PMID: 3033126
  164. Epstein-Barr virus-positive Burkitt's lymphoma cells not recognized by virus-specific T-cell surveillance.
    Nature. 1985 Oct 17-23;317(6038):629-31 PMID: 2997615
  165. Restoration of antigen presentation to the mutant cell line RMA-S by an MHC-linked transporter.
    Nature. 1991 Dec 19-26;354(6354):528-31 PMID: 1758495
  166. An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease.
    J Exp Med. 1994 Apr 1;179(4):1155-61 PMID: 7511682
  167. Studies on cell lines derived from Burkitt's lymphoma.
    Trans N Y Acad Sci. 1966 Nov;29(1):71-9 PMID: 5232223
  168. T cell recognition of Epstein-Barr virus associated lymphomas.
    Cancer Surv. 1992;13:53-80 PMID: 1330300
  169. Structural analyses of EBER1 and EBER2 ribonucleoprotein particles present in Epstein-Barr virus-infected cells.
    J Virol. 1988 Mar;62(3):902-11 PMID: 2828685
  170. Long-term C-cell-mediated immunity to Epstein-Barr virus in man. II. Components necessary for regression in virus-infected leukocyte cultures.
    Int J Cancer. 1979 May 15;23(5):610-7 PMID: 222690
  171. T cell responses and virus evolution: loss of HLA A11-restricted CTL epitopes in Epstein-Barr virus isolates from highly A11-positive populations by selective mutation of anchor residues.
    J Exp Med. 1994 Apr 1;179(4):1297-305 PMID: 7511684
  172. Differential expression of HLA antigens on human B-cell lines of normal and malignant origin: a consequence of immune surveillance or a phenotypic vestige of the progenitor cells?
    Int J Cancer. 1988 Jun 15;41(6):913-9 PMID: 2453477
  173. Epstein-Barr virus specific T-cell response in nasopharyngeal carcinoma patients.
    Int J Cancer. 1983 Sep 15;32(3):301-5 PMID: 6309678
  174. Cytotoxic effector cells specific for B Cell lines transformed by Epstein-Barr virus are present in patients with infectious mononucleosis.
    Proc Natl Acad Sci U S A. 1975 Apr;72(4):1622-6 PMID: 165518
  175. Sequential appearance of Epstein-Barr virus nuclear and lymphocyte-detected membrane antigens in B cell transformation.
    Nature. 1981 Jun 25;291(5817):664-6 PMID: 6264317
  176. Epstein-Barr virus superinduces a new human B cell differentiation antigen (B-LAST 1) expressed on transformed lymphoblasts.
    Cell. 1982 Sep;30(2):415-25 PMID: 6291768
  177. The 160,000-Mr virion protein encoded at the right end of the herpesvirus saimiri genome is homologous to the 140,000-Mr membrane antigen encoded at the left end of the Epstein-Barr virus genome.
    J Virol. 1987 Jul;61(7):2063-70 PMID: 3035208
  178. Antibodies to Epstein-Barr virus in Burkitt's lymphoma and control groups.
    J Natl Cancer Inst. 1969 Nov;43(5):1147-57 PMID: 5353242
  179. Epstein-Barr virus (B95-8) DNA VII: molecular cloning and detailed mapping.
    Proc Natl Acad Sci U S A. 1980 May;77(5):2999-3003 PMID: 6248879
  180. Expression of Epstein-Barr virus nuclear antigens in anti-IgM-stimulated B cells following recombinant vaccinia infection and their recognition by human cytotoxic T cells.
    Immunology. 1991 Nov;74(3):504-10 PMID: 1722774
  181. Analysis of antibody titers to Epstein-Barr virus nuclear antigens in sera of patients with Sjögren's syndrome and with rheumatoid arthritis.
    J Infect Dis. 1991 Jul;164(1):22-8 PMID: 1647426
  182. DNA sequence and expression of the B95-8 Epstein-Barr virus genome.
    Nature. 1984 Jul 19-25;310(5974):207-11 PMID: 6087149
  183. Expression of Epstein-Barr virus latent gene products in tumour cells of Hodgkin's disease.
    Lancet. 1991 Feb 9;337(8737):320-2 PMID: 1671232
  184. Antibody response against the Epstein-Barr virus-coded nuclear antigen2 (EBNA2) in different groups of individuals.
    Int J Cancer. 1987 Sep 15;40(3):349-53 PMID: 3040599
  185. Hodgkin's disease in patients with previous infectious mononucleosis: 30 years' experience.
    Br Med J. 1974 May 4;2(5913):253-6 PMID: 4406463
  186. Interferon-gamma in a family with X-linked lymphoproliferative syndrome with acute Epstein-Barr virus infection.
    J Clin Immunol. 1989 Jan;9(1):48-54 PMID: 2539385
  187. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4+ T-cell clones.
    J Virol. 1991 Jul;65(7):3821-8 PMID: 1710291
  188. Epidemiology of Hodgkin's disease.
    Semin Oncol. 1980 Jun;7(2):92-102 PMID: 6255608
  189. Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes.
    J Exp Med. 1987 Jun 1;165(6):1508-23 PMID: 2438367
  190. Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37.
    Hum Genet. 1989 Jul;82(4):354-8 PMID: 2567696
  191. The complete DNA sequence of varicella-zoster virus.
    J Gen Virol. 1986 Sep;67 ( Pt 9):1759-816 PMID: 3018124
  192. Surface markers on human B and T lymphocytes. VIII. Association between complement and Epstein-Barr virus receptors on human lymphoid cells.
    Scand J Immunol. 1976;5(4):401-10 PMID: 59946
  193. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization.
    J Gen Virol. 1989 Jul;70 ( Pt 7):1755-64 PMID: 2544663
  194. Geographical prevalence of two types of Epstein-Barr virus.
    Virology. 1986 Oct 15;154(1):56-66 PMID: 3019008
  195. Epstein-Barr virus-associated lymphoproliferative disorders.
    Lab Invest. 1992 Jul;67(1):5-23 PMID: 1320711
  196. VIRUS PARTICLES IN CULTURED LYMPHOBLASTS FROM BURKITT'S LYMPHOMA.
    Lancet. 1964 Mar 28;1(7335):702-3 PMID: 14107961
  197. Epstein-Barr virus infection and immunoregulation in man.
    Adv Immunol. 1985;37:99-149 PMID: 2988307
  198. Immunohistology of Epstein-Barr virus-associated antigens in B cell disorders from immunocompromised individuals.
    Transplantation. 1990 May;49(5):944-53 PMID: 2159663
  199. Simple repeat array in Epstein-Barr virus DNA encodes part of the Epstein-Barr nuclear antigen.
    Science. 1983 Jun 24;220(4604):1396-8 PMID: 6304878
  200. Salted fish and inhalants as risk factors for nasopharyngeal carcinoma in Malaysian Chinese.
    Cancer Res. 1983 Jun;43(6):2967-70 PMID: 6850606
  201. Early events in Epstein-Barr virus infection of human B lymphocytes.
    Virology. 1991 Apr;181(2):595-608 PMID: 1849678
  202. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies.
    J Exp Med. 1992 Jul 1;176(1):157-68 PMID: 1319456
  203. Isolation and sequencing of the Epstein-Barr virus BNLF-1 gene (LMP1) from a Chinese nasopharyngeal carcinoma.
    J Gen Virol. 1991 Oct;72 ( Pt 10):2399-409 PMID: 1681026
  204. Epstein-Barr virus isolates with the major HLA B35.01-restricted cytotoxic T lymphocyte epitope are prevalent in a highly B35.01-positive African population.
    Eur J Immunol. 1995 Jan;25(1):102-10 PMID: 7531142
  205. Human cytotoxic T-cell responses against Epstein-Barr virus nuclear antigens demonstrated by using recombinant vaccinia viruses.
    Proc Natl Acad Sci U S A. 1990 Apr;87(8):2906-10 PMID: 2158098
  206. The specificity of recognition of a cytotoxic T lymphocyte epitope.
    Eur J Immunol. 1992 Jan;22(1):191-5 PMID: 1370414
  207. Lymphoma development in mice and humans: diversity of initiation is followed by convergent cytogenetic evolution.
    Proc Natl Acad Sci U S A. 1979 May;76(5):2442-6 PMID: 221925
  208. Aggressive peripheral T-cell lymphomas containing Epstein-Barr viral DNA: a clinicopathologic and molecular analysis.
    Blood. 1991 Feb 15;77(4):799-808 PMID: 1847084
  209. An Epstein-Barr virus-specific cytotoxic T cell epitope in EBV nuclear antigen 3 (EBNA 3).
    J Exp Med. 1990 Jan 1;171(1):345-9 PMID: 1688611
  210. Absence of infectious Epstein-Barr virus in blood in acute infectious mononucleosis.
    Nature. 1975 Nov 20;258(5532):236 PMID: 172793
  211. Repeat arrays in cellular DNA related to the Epstein-Barr virus IR3 repeat.
    Mol Cell Biol. 1985 Mar;5(3):457-65 PMID: 2985954
  212. Endoplasmic reticulum signal sequence facilitated transport of peptide epitopes restores immunogenicity of an antigen processing defective tumour cell line.
    Int Immunol. 1994 Apr;6(4):639-45 PMID: 7517178
  213. A comparison of Epstein-Barr virus-specific T-cell immunity in rheumatoid arthritis and osteoarthritis patients.
    Aust J Exp Biol Med Sci. 1983 Oct;61 ( Pt 5):509-16 PMID: 6318713
  214. Detection of a second widespread strain of Epstein-Barr virus.
    Lancet. 1989 Sep 30;2(8666):761-5 PMID: 2571010
  215. Correlation between immunoglobulin light chain expression and variant translocation in Burkitt's lymphoma.
    Nature. 1982 Jul 29;298(5873):474-6 PMID: 6806672
  216. Antibodies to Epstein-Barr virus-associated nuclear antigen in infectious mononucleosis.
    J Infect Dis. 1974 Sep;130(3):231-9 PMID: 4369787
  217. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide.
    J Exp Med. 1993 Sep 1;178(3):879-87 PMID: 7688791
  218. Partial Xq25 deletion in a family with the X-linked lymphoproliferative disease (XLP)
    Cancer Genet Cytogenet. 1990 Jul 15;47(2):163-9 PMID: 1972651
  219. Replication of Epstein-Barr virus in human epithelial cells infected in vitro.
    Nature. 1983 Dec 1-7;306(5942):480-3 PMID: 6316160
  220. EBV-activation of human B-lymphocytes.
    Curr Top Microbiol Immunol. 1986;132:266-71 PMID: 3024919
  221. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization.
    Int J Cancer. 1991 Apr 22;48(1):45-50 PMID: 1850382
  222. Rapid visual assay of cytotoxic T-cell specificity utilizing synthetic peptide induced T-cell-T-cell killing.
    Immunology. 1992 May;76(1):174-5 PMID: 1378424
  223. Activation of Epstein-Barr virus replication in Hodgkin and Reed-Sternberg cells.
    Blood. 1991 Sep 1;78(5):1162-5 PMID: 1652308
  224. A gene in the human major histocompatibility complex class II region controlling the class I antigen presentation pathway.
    Nature. 1990 Dec 20-27;348(6303):744-7 PMID: 2259384
  225. Minimal epitopes expressed in a recombinant polyepitope protein are processed and presented to CD8+ cytotoxic T cells: implications for vaccine design.
    Proc Natl Acad Sci U S A. 1995 Jun 20;92(13):5845-9 PMID: 7541138
  226. Restored expression of major histocompatibility class I molecules by gene transfer of a putative peptide transporter.
    Nature. 1991 May 23;351(6324):323-4 PMID: 2034277
  227. Long-term T-cell-mediated immunity to Epstein-Barr virus in man. IV. Development of T-cell memory in convalescent infectious mononucleosis patients.
    Int J Cancer. 1980 Jan 15;25(1):59-65 PMID: 6249763
  228. Epstein-Barr virus replication in oropharyngeal epithelial cells.
    N Engl J Med. 1984 May 10;310(19):1225-30 PMID: 6323983
  229. X-linked recessive progressive combined variable immunodeficiency (Duncan's disease).
    Lancet. 1975 Apr 26;1(7913):935-40 PMID: 48119
  230. Recent results on the biology of Hodgkin and Reed-Sternberg cells. I. Biopsy material.
    Leuk Lymphoma. 1992 Nov;8(4-5):283-313 PMID: 1337848
  231. Expression of Epstein-Barr virus nuclear antigens 3, 4, and 6 are altered in cell lines containing B-type virus.
    Virology. 1989 Aug;171(2):401-8 PMID: 2548326
  232. Prevalence of the A and B types of Epstein-Barr virus DNA in nasopharyngeal carcinoma biopsies from southern China.
    J Gen Virol. 1992 Feb;73 ( Pt 2):463-6 PMID: 1311369
  233. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death.
    Cell. 1991 Jun 28;65(7):1107-15 PMID: 1648447
  234. Viral latency and transformation: the strategy of Epstein-Barr virus.
    Cell. 1989 Jul 14;58(1):5-8 PMID: 2546674
  235. Endemic Burkitt's lymphoma: phenotypic analysis of tumor biopsy cells and of derived tumor cell lines.
    J Natl Cancer Inst. 1986 Sep;77(3):681-7 PMID: 2943927
  236. The establishment of lymphoblastoid lines from adult and fetal human lymphoid tissue and its dependence on EBV.
    Int J Cancer. 1971 Nov 15;8(3):443-50 PMID: 4332899
  237. Identification of T- and B-cell epitopes associated with a restricted component of the Epstein-Barr virus-induced early antigen complex.
    Int J Cancer. 1993 Jan 21;53(2):199-204 PMID: 7678829
  238. Five new cytotoxic T cell epitopes identified within Epstein-Barr virus nuclear antigen 3.
    J Gen Virol. 1994 Sep;75 ( Pt 9):2489-93 PMID: 7521394
  239. Establishment and characterization of three transplantable EBV-containing nasopharyngeal carcinomas.
    Int J Cancer. 1988 Oct 15;42(4):599-606 PMID: 2971626
  240. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma.
    Int J Cancer. 1988 Sep 15;42(3):329-38 PMID: 2843473
  241. Oral excretion of Epstein-Barr virus by healthy subjects and patients with infectious mononucleosis.
    Lancet. 1972 Nov 11;2(7785):988-9 PMID: 4116980
  242. Nonresponsiveness to an immunodominant Epstein-Barr virus-encoded cytotoxic T-lymphocyte epitope in nuclear antigen 3A: implications for vaccine strategies.
    Proc Natl Acad Sci U S A. 1991 Nov 1;88(21):9478-82 PMID: 1719531
  243. Variations among isolates of Epstein-Barr virus.
    Ann N Y Acad Sci. 1980;354:309-25 PMID: 6261649
  244. Composite response of naive T cells to stimulation with the autologous lymphoblastoid cell line is mediated by CD4 cytotoxic T cell clones and includes an Epstein-Barr virus-specific component.
    Cell Immunol. 1991 Feb;132(2):295-307 PMID: 1846323
  245. Transformation of foetal human keukocytes in vitro by filtrates of a human leukaemic cell line containing herpes-like virus.
    Int J Cancer. 1968 Nov 15;3(6):857-66 PMID: 4894385
  246. Proteins of Epstein-Barr Virus. II. Electrophoretic analysis of the polypeptides of the nucleocapsid and the glucosamine- and polysaccharide-containing components of enveloped virus.
    J Virol. 1976 Apr;18(1):289-97 PMID: 176465
  247. Human T-cell recognition of Epstein-Barr virus-induced replication antigen complexes.
    Int J Cancer. 1991 Nov 11;49(5):656-60 PMID: 1657795
  248. Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions.
    J Virol. 1992 Jun;66(6):3355-62 PMID: 1316452
  249. HLA-DR-antigen-associated restriction of EBV-specific cytotoxic T-cell colonies.
    Int J Cancer. 1984 Feb 15;33(2):239-43 PMID: 6319303
Article Info
Journal
Microbiological reviews
Abbr.
Microbiol Rev
ISSN
0146-0749
DOI
10.1128/mr.59.3.387-405.1995
Published
1995-09-00
Pages
387-405
Language
English
Region
United States
NLM ID
7806086
PMCID
PMC239366
Subset
IM
Grants
NCI NIH HHS · CA52250-05 · United States
NCI NIH HHS · CA57952-03 · United States
External Links
PubMed source DOI: 10.1128/mr.59.3.387-405.1995 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2